Terlipressin clinical trials
Terlipressin is named as an intervention in 4 current clinical trials in our India, China, Turkey and Egypt registers. 2 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Noorik Biopharmaceuticals AG (1). The most-studied condition is Hepatorenal Syndrome.
Where Terlipressin is approved
All regulators →Of the three regulators tracked here, the first to approve Terlipressin was the US, on 14 Sep 2022.
- 1 EU safety letter (DHPC), latest: referral - article 31 for Terlipressin, 1 Dec 2022
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Terlipressin patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Terlipressin, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 1 listed patent; the last listed expires 5 Apr 2037 (US 10335452).
- Exclusivity ODE-406: Orphan drug exclusivity: to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function, until 14 Sep 2029.
- Exclusivity NCE: New chemical entity, until 14 Sep 2027.
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
How Terlipressin works
All drug targets →- Vasopressin V1 receptor binding agent Binding agentTarget: Vasopressin V1 receptorChEMBL only
- Vasopressin V2 receptor binding agent Binding agentTarget: AVPR2 arginine vasopressin receptor 2ChEMBL only
- AscitesPhase 3
- HemoptysisPhase 3
- Hypotensive disorderPhase 3
- Septic shockPhase 3
- SepsisPhase 2/3
- Cirrhosis of liverPhase 2/3
- Esophageal varicesPhase 2/3
- Acute kidney injuryPhase 2
- Colorectal cancerPhase 2
- Gastric adenocarcinomaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL2135460, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 11241, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Terlipressin
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 3 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Terlipressin
- ATC code
- H01BA04
- ChEMBL
- CHEMBL2135460
- PubChem CID
- 72081
- CAS number
- 14636-12-5
- Wikidata
- Q324147
- Wikipedia
- Terlipressin
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Terlipressin
4 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Terlipressin across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
3 single-substance products containing Terlipressin on the HPRA medicines list.
- GLYPRESSIN 1 mg Powder and Solvent for Solution for InjectionFerring Ireland Ltd · PA1009/004/001 · Marketed
- Glypressin 1 mg/ 8.5 ml solution for injectionFerring Ireland Ltd · PA1009/004/002 · Marketed
- Terlipressin acetate EVER Pharma 0.2 mg/ml solution for injectionEVER Valinject GmbH · PA1774/007/001 · Marketed
Supply shortages
No entry for Terlipressin in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Terlipressin
10 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Noorik Biopharmaceuticals AG | 1 |
| Beijing Friendship Hospital | 1 |
| Istanbul Medipol University Hospital | 1 |
| Wael Elbanna Clinic | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in India | 1 | 0 |
| Clinical trials in China | 1 | 0 |
| Clinical trials in Turkey | 1 | 1 |
| Clinical trials in Egypt | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Terlipressin trials
How many clinical trials are testing Terlipressin?
4 current trials in our India, China, Turkey and Egypt registers name Terlipressin as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Terlipressin trials recruiting patients?
Yes. 2 of the 4 trials are recruiting: 1 with sites in Turkey and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Terlipressin clinical trials?
Noorik Biopharmaceuticals AG (1), Beijing Friendship Hospital (1), Istanbul Medipol University Hospital (1) and Wael Elbanna Clinic (1). The number in brackets is how many trials each organisation leads.
Is Terlipressin licensed in Ireland?
Yes. The HPRA medicines list includes 3 single-substance products containing Terlipressin, for example GLYPRESSIN 1 mg Powder and Solvent for Solution for Injection (Ferring Ireland Ltd). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Terlipressin shortage?
Not in the lists we track: Terlipressin has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Terlipressin works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Terlipressin works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Terlipressin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.